AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Drug Interaction Study Between AZD3480 and Warfarin
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00689637
- Locations
- 🇸🇪
Research SIte, Uppsala, Sweden
Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00689559
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Effects of Crestor on Inflammation of Atherosclerotic Plaques
Early Phase 1
Completed
- Conditions
- AtherosclerosisInflammatory Activity in Carotid Arteries
- Interventions
- Drug: placeboDrug: rosuvastatin
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00689416
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
Completed
- Conditions
- Hypercholesteremia
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3392
- Registration Number
- NCT00688454
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
Early Phase 1
Completed
- Conditions
- Insulin Resistance
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00689208
- Locations
- 🇸🇪
Research Site, Göteborg, Sweden
Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination
Phase 1
Completed
- Conditions
- UlcersUpper GI Symptoms
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT00688428
Effects of Single Oral Dose Dapagliflozin QT Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00688493
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5103
- Registration Number
- NCT00688532
Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season
Phase 1
Completed
- Conditions
- HealthyAllergic Rhinitis
- Interventions
- Drug: AZD8848Drug: Placebo
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 130
- Registration Number
- NCT00688779
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments
Completed
- Conditions
- GERD
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2912
- Registration Number
- NCT00688675
- Locations
- 🇨🇭
Research Site, Aarau, Switzerland
© Copyright 2025. All Rights Reserved by MedPath